Recombinant Trop2 (Sacituzumab Biosimilar) antibody

Catalog No. ABIN7795132

The Humanized Monoclonal anti-Trop2 (Sacituzumab Biosimilar) antibody (ABIN7795132) specifically detects Trop2 (Sacituzumab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant Trop2 (Sacituzumab Biosimilar) antibody (ABIN7795132)

Target: Trop2 (Sacituzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This Trop2 (Sacituzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-Trop2 (Sacituzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody

Characteristics: What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human Trop-2

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for Trop2 (Sacituzumab Biosimilar)

Target: Trop2 (Sacituzumab Biosimilar)

Alternative Name: Sacituzumab Biosimilar

Target Type: Biosimilar